Haemonetics Stock Price, News & Analysis (NYSE:HAE)

$69.99 +0.74 (+1.07 %)
(As of 02/25/2018 10:45 AM ET)
Previous Close$69.99
Today's Range$69.18 - $70.22
52-Week Range$37.20 - $72.33
Volume373,336 shs
Average Volume559,257 shs
Market Capitalization$3.74 billion
P/E Ratio-205.85
Dividend YieldN/A
Beta1.06

About Haemonetics (NYSE:HAE)

Haemonetics logoHaemonetics Corporation (Haemonetics) is a healthcare company. The Company provides various products to customers involved in the processing, handling and analysis of blood. The Company's segments include Japan, EMEA, North America Plasma and All Other. Haemonetics provides plasma collection systems and software, which enable plasma fractionators to make pharmaceuticals. The Company enables plasma collection customers to source from it a range of products necessary for plasma collection and storage, including PCS brand plasma collection equipment and disposables, plasma collection containers and intravenous solutions, such as saline. Haemonetics offers automated blood component and manual whole blood collection systems to blood collection centers to collect blood products. The Company offers a range of blood management solutions. The Company has a suite of integrated software solutions, which include solutions for blood drive planning and blood collection.

Receive HAE News and Ratings via Email

Sign-up to receive the latest news and ratings for HAE and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Medical Equipment, Supplies & Distribution
Sub-IndustryHealth Care Supplies
SectorMedical
SymbolNYSE:HAE
CUSIP40502410
Phone781-848-7100

Debt

Debt-to-Equity Ratio0.14%
Current Ratio1.82%
Quick Ratio1.33%

Price-To-Earnings

Trailing P/E Ratio-205.846886856269
Forward P/E Ratio37.63
P/E Growth3.47

Sales & Book Value

Annual Sales$886.12 million
Price / Sales4.22
Cash Flow$3.25 per share
Price / Cash21.53
Book Value$15.40 per share
Price / Book4.54

Profitability

Trailing EPS($0.34)
Net Income$-26,260,000.00
Net Margins-1.94%
Return on Equity12.39%
Return on Assets7.66%

Miscellaneous

Employees3,107
Outstanding Shares53,450,000

Haemonetics (NYSE:HAE) Frequently Asked Questions

What is Haemonetics' stock symbol?

Haemonetics trades on the New York Stock Exchange (NYSE) under the ticker symbol "HAE."

How will Haemonetics' stock buyback program work?

Haemonetics announced that its board has approved a stock buyback program on Tuesday, February 6th 2018, which authorizes the company to repurchase $260,000,000.00 in shares, according to EventVestor. This repurchase authorization authorizes the company to purchase shares of its stock through open market purchases. Shares repurchase programs are generally an indication that the company's management believes its stock is undervalued.

How were Haemonetics' earnings last quarter?

Haemonetics Co. (NYSE:HAE) issued its quarterly earnings data on Tuesday, February, 6th. The medical instruments supplier reported $0.62 earnings per share for the quarter, beating the Zacks' consensus estimate of $0.44 by $0.18. The medical instruments supplier earned $234.04 million during the quarter, compared to analysts' expectations of $227.79 million. Haemonetics had a negative net margin of 1.94% and a positive return on equity of 12.39%. The company's quarterly revenue was up 2.7% on a year-over-year basis. During the same period in the prior year, the business posted $0.43 EPS. View Haemonetics' Earnings History.

When will Haemonetics make its next earnings announcement?

Haemonetics is scheduled to release their next quarterly earnings announcement on Monday, May, 14th 2018. View Earnings Estimates for Haemonetics.

What guidance has Haemonetics issued on next quarter's earnings?

Haemonetics issued an update on its FY18 earnings guidance on Tuesday, February, 6th. The company provided earnings per share guidance of $1.80-1.90 for the period, compared to the Thomson Reuters consensus estimate of $1.70.

Where is Haemonetics' stock going? Where will Haemonetics' stock price be in 2018?

6 Wall Street analysts have issued 12-month target prices for Haemonetics' stock. Their predictions range from $50.00 to $80.00. On average, they expect Haemonetics' stock price to reach $70.00 in the next year. View Analyst Ratings for Haemonetics.

Who are some of Haemonetics' key competitors?

Who are Haemonetics' key executives?

Haemonetics' management team includes the folowing people:

  • Christopher Simon, President, Chief Executive Officer, Director (Age 53)
  • William P. Burke, Chief Financial Officer, Executive Vice President (Age 49)
  • David J. Wilson, President - Plasma Business Unit
  • Michelle Basil, Executive Vice President, General Counsel (Age 45)
  • Neil Ryding, Executive Vice President, Global Operations (Age 56)
  • Richard J. Meelia, Non-Executive Independent Chairman of the Board (Age 68)
  • Robert E. Abernathy, Director (Age 62)
  • Ellen M. Zane, Director (Age 66)
  • Catherine M. Burzik, Independent Director (Age 67)
  • Charles J. Dockendorff, Independent Director (Age 63)

Who owns Haemonetics stock?

Haemonetics' stock is owned by many different of retail and institutional investors. Top institutional investors include BlackRock Inc. (12.48%), Victory Capital Management Inc. (4.60%), Wells Fargo & Company MN (3.96%), HealthCor Management L.P. (2.71%), Renaissance Technologies LLC (1.83%) and Fuller & Thaler Asset Management Inc. (1.40%). Company insiders that own Haemonetics stock include Christopher Simon, Dan Goldstein, Mark W Kroll, Pedro P Granadillo, Ronald G Gelbman, Ronald Merriman, Susan Bartlett Foote and Willaim P Burke. View Institutional Ownership Trends for Haemonetics.

Who sold Haemonetics stock? Who is selling Haemonetics stock?

Haemonetics' stock was sold by a variety of institutional investors in the last quarter, including Fuller & Thaler Asset Management Inc., Wells Fargo & Company MN, Millennium Management LLC, Rutabaga Capital Management LLC MA, Martingale Asset Management L P, Schwab Charles Investment Management Inc., Gotham Asset Management LLC and Bessemer Group Inc.. Company insiders that have sold Haemonetics company stock in the last year include Dan Goldstein, Mark W Kroll, Pedro P Granadillo, Ronald G Gelbman, Ronald Merriman, Susan Bartlett Foote and Willaim P Burke. View Insider Buying and Selling for Haemonetics.

Who bought Haemonetics stock? Who is buying Haemonetics stock?

Haemonetics' stock was purchased by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC, Two Sigma Investments LP, BlackRock Inc., Two Sigma Advisers LP, Bogle Investment Management L P DE, Castleark Management LLC, American Century Companies Inc. and Barrow Hanley Mewhinney & Strauss LLC. View Insider Buying and Selling for Haemonetics.

How do I buy Haemonetics stock?

Shares of Haemonetics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Haemonetics' stock price today?

One share of Haemonetics stock can currently be purchased for approximately $69.99.

How big of a company is Haemonetics?

Haemonetics has a market capitalization of $3.74 billion and generates $886.12 million in revenue each year. The medical instruments supplier earns $-26,260,000.00 in net income (profit) each year or ($0.34) on an earnings per share basis. Haemonetics employs 3,107 workers across the globe.

How can I contact Haemonetics?

Haemonetics' mailing address is 400 WOOD RD, BRAINTREE MA, 02184. The medical instruments supplier can be reached via phone at 781-848-7100 or via email at [email protected]


MarketBeat Community Rating for Haemonetics (HAE)

Community Ranking:  2.0 out of 5 (star star)
Outperform Votes:  163 (Vote Outperform)
Underperform Votes:  240 (Vote Underperform)
Total Votes:  403
MarketBeat's community ratings are surveys of what our community members think about Haemonetics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Haemonetics (NYSE:HAE) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyHold
Consensus Rating Score: 2.672.672.602.29
Ratings Breakdown: 0 Sell Rating(s)
2 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
3 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $70.00$56.60$51.20$39.83
Price Target Upside: 2.13% upside9.73% downside5.60% downside6.03% downside

Haemonetics (NYSE:HAE) Consensus Price Target History

Price Target History for Haemonetics (NYSE:HAE)

Haemonetics (NYSE:HAE) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/7/2018Morgan StanleyBoost Price TargetOverweight -> Overweight$74.00 -> $77.00HighView Rating Details
2/7/2018Barrington ResearchReiterated RatingOutperform -> Outperform$57.00 -> $71.00HighView Rating Details
2/7/2018JMP SecuritiesReiterated RatingOutperform$72.00HighView Rating Details
2/7/2018Jefferies GroupReiterated RatingBuy$80.00HighView Rating Details
1/2/2018Raymond James FinancialUpgradeUnderperform -> Market PerformHighView Rating Details
11/8/2017Craig HallumReiterated RatingHold$40.00 -> $50.00N/AView Rating Details
11/7/2016BTIG ResearchReiterated RatingNeutralN/AView Rating Details
11/7/2016BenchmarkBoost Price TargetHold$32.00 -> $34.00N/AView Rating Details
10/14/2016Off Wall StreetInitiated CoverageSell$24.00N/AView Rating Details
9/20/2016CJS SecuritiesDowngradeMarket Outperform -> Market Perform$35.00N/AView Rating Details
8/15/2016SidotiDowngradeBuy -> Neutral$39.00N/AView Rating Details
5/16/2016Goldman Sachs GroupUpgradeSell -> Neutral$29.00N/AView Rating Details
(Data available from 2/25/2016 forward)

Earnings

Haemonetics (NYSE:HAE) Earnings History and Estimates Chart

Earnings by Quarter for Haemonetics (NYSE:HAE)

Haemonetics (NYSE HAE) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/7/2018$0.43N/AView Earnings Details
2/6/2018Q3 2018$0.44$0.62$227.79 million$234.04 millionViewListenView Earnings Details
11/7/2017Q2 2018$0.41$0.48$219.12 million$225.40 millionViewN/AView Earnings Details
8/7/2017Q1 2018$0.31$0.33$211.29 million$211.00 millionViewListenView Earnings Details
5/8/2017Q4 2017$0.37$0.39$215.06 million$228.10 millionViewListenView Earnings Details
2/6/2017Q317$0.40$0.43$220.00 million$227.80 millionViewListenView Earnings Details
11/7/2016Q217$0.35$0.46$210.72 million$220.30 millionViewListenView Earnings Details
8/1/2016Q117$0.28$0.25$205.41 million$210.00 millionViewListenView Earnings Details
5/2/2016Q416$0.46$0.37$245.08 million$243.20 millionViewListenView Earnings Details
2/1/2016Q316$0.46$0.48$237.37 million$233.40 millionViewListenView Earnings Details
11/4/2015Q216$0.40$0.44$226.50 million$219.70 millionViewListenView Earnings Details
7/27/2015Q116$0.33$0.35$215.62 million$213.40 millionViewListenView Earnings Details
4/27/2015Q415$0.51$0.47$239.20 million$226.50 millionViewListenView Earnings Details
1/29/2015Q315$0.51$0.53$235.45 million$231.80 millionViewListenView Earnings Details
11/3/2014Q215$0.45$0.47$229.90 million$227.60 millionViewListenView Earnings Details
7/30/2014Q115$0.35$0.38$215.85 million$224.49 millionViewListenView Earnings Details
4/28/2014Q414$0.58$0.46$244.87 million$241.00 millionViewListenView Earnings Details
1/27/2014Q314$0.61$0.61$243.71 million$242.10 millionViewListenView Earnings Details
10/28/2013Q214$0.57$0.66$239.51 million$235.80 millionViewListenView Earnings Details
7/29/2013Q1 2014$0.47$0.46$232.98 million$219.50 millionViewListenView Earnings Details
5/1/2013Q4 2013$0.46$0.48$249.33 million$249.90 millionViewListenView Earnings Details
1/30/2013Q3 2013$0.47$0.50$251.93 million$247.40 millionViewListenView Earnings Details
10/29/2012Q213$0.77$0.90$223.47 million$218.18 millionViewN/AView Earnings Details
8/1/2012$0.71$0.55ViewN/AView Earnings Details
4/30/2012$0.83$0.80ViewN/AView Earnings Details
1/30/2012$0.80$0.86ViewN/AView Earnings Details
10/31/2011$0.77$0.72ViewN/AView Earnings Details
8/1/2011$0.77$0.65ViewN/AView Earnings Details
5/2/2011$0.83$0.85ViewN/AView Earnings Details
1/31/2011$0.82$0.89ViewN/AView Earnings Details
11/1/2010Q2 2011$0.38$0.40ViewN/AView Earnings Details
8/2/2010Q1 2011$0.36$0.37ViewN/AView Earnings Details
5/4/2010Q4 2010$0.38$0.38ViewN/AView Earnings Details
2/1/2010Q3 2010$0.36$0.35ViewN/AView Earnings Details
11/2/2009Q2 2010$0.33$0.34ViewN/AView Earnings Details
8/3/2009Q1 2010$0.33$0.35ViewN/AView Earnings Details
5/4/2009Q4 2009$0.32$0.32ViewN/AView Earnings Details
2/2/2009Q3 2009$0.31$0.32ViewN/AView Earnings Details
10/27/2008Q2 2009$0.28$0.29ViewN/AView Earnings Details
8/1/2008Q1 2009$0.28$0.29ViewN/AView Earnings Details
5/1/2008Q4 2008$0.29$0.29ViewN/AView Earnings Details
1/31/2008Q3 2008$0.27$0.29ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Haemonetics (NYSE:HAE) Earnings Estimates

2018 EPS Consensus Estimate: $1.58
2019 EPS Consensus Estimate: $2.12
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20183$0.25$0.37$0.30
Q2 20183$0.38$0.47$0.44
Q3 20183$0.41$0.45$0.43
Q4 20182$0.40$0.43$0.42
Q1 20192$0.46$0.46$0.46
Q2 20192$0.54$0.56$0.55
Q3 20192$0.56$0.63$0.60
Q4 20192$0.49$0.54$0.52
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for Haemonetics (NYSE:HAE)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Haemonetics (NYSE HAE) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 1.20%
Institutional Ownership Percentage: 95.88%
Insider Trades by Quarter for Haemonetics (NYSE:HAE)
Institutional Ownership by Quarter for Haemonetics (NYSE:HAE)

Haemonetics (NYSE HAE) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/2/2018Mark W KrollDirectorSell7,118$63.00$448,434.0033,881View SEC Filing  
12/1/2017Pedro P GranadilloDirectorSell7,118$57.06$406,153.0831,663View SEC Filing  
11/16/2017Ronald G GelbmanDirectorSell5,440$56.69$308,393.60View SEC Filing  
11/14/2017Willaim P BurkeCFOSell13,193$54.04$712,949.7227,227View SEC Filing  
11/13/2017Dan GoldsteinCAOSell4,691$54.93$257,676.633,747View SEC Filing  
11/10/2017Susan Bartlett FooteDirectorSell16,926$54.19$917,219.9427,313View SEC Filing  
5/22/2017Ronald MerrimanDirectorSell17,471$40.33$704,605.4324,925View SEC Filing  
12/12/2016Ronald G GelbmanDirectorSell5,683$40.30$229,024.9049,688View SEC Filing  
8/17/2016Ronald MerrimanDirectorSell4,337$35.14$152,402.1822,088View SEC Filing  
8/4/2016Christopher SimonCEOBuy60,000$35.00$2,100,000.00View SEC Filing  
10/26/2015Byron SelmanInsiderSell344$32.13$11,052.7212,010View SEC Filing  
10/26/2015Christopher J LindopCFOSell436$32.13$14,008.6845,350View SEC Filing  
10/26/2015Sandra JesseEVPSell778$32.13$24,997.1420,096View SEC Filing  
10/26/2015Susan M HanlonVPSell497$32.13$15,968.6120,464View SEC Filing  
9/15/2015Brian ConcannonCEOSell6,569$35.15$230,900.35147,040View SEC Filing  
9/1/2015Brian ConcannonCEOSell4,765$35.63$169,776.95147,040View SEC Filing  
8/20/2015Christopher J. LindopCFOSell4,902$38.49$188,677.9838,188View SEC Filing  
8/17/2015Brian ConcannonCEOSell6,569$39.28$258,030.32View SEC Filing  
7/20/2015Christopher J LindopCFOSell4,902$39.09$191,619.18View SEC Filing  
7/15/2015Brian ConcannonCEOSell6,569$39.59$260,066.71View SEC Filing  
7/6/2015Peter M AllenInsiderSell30,494$40.19$1,225,553.86View SEC Filing  
7/2/2015Jonathan WhiteInsiderSell2,385$41.14$98,118.90View SEC Filing  
6/22/2015Christopher J LindopCFOSell4,902$42.51$208,384.02View SEC Filing  
6/15/2015Brian ConcannonCEOSell6,569$42.51$279,248.19View SEC Filing  
6/10/2015Susan M HanlonVPSell6,000$43.00$258,000.00View SEC Filing  
6/1/2015Brian ConcannonCEOSell4,765$41.39$197,223.35View SEC Filing  
5/20/2015Christopher J LindopCFOSell4,902$41.65$204,168.30View SEC Filing  
5/1/2015Brian ConcannonCEOSell4,765$40.74$194,126.10View SEC Filing  
4/20/2015Christopher J LindopCFOSell4,902$41.55$203,678.10View SEC Filing  
4/1/2015Brian ConcannonCEOSell4,765$44.51$212,090.15View SEC Filing  
3/27/2015Susan M HanlonVPSell7,000$43.46$304,220.00View SEC Filing  
3/20/2015Christopher J LindopCFOSell4,902$44.26$216,962.52View SEC Filing  
3/10/2015Susan Bartlett FooteDirectorSell11,328$43.84$496,619.52View SEC Filing  
3/5/2015Ronald G GelbmanDirectorSell7,707$44.76$344,965.32View SEC Filing  
3/4/2015Ronald MerrimanDirectorSell14,258$43.80$624,500.40View SEC Filing  
3/2/2015Brian ConcannonCEOSell4,765$44.41$211,613.65View SEC Filing  
2/18/2015Pedro P GranadilloDirectorSell11,328$43.45$492,201.60View SEC Filing  
2/2/2015Brian ConcannonCEOSell4,765$39.15$186,549.75View SEC Filing  
1/2/2015Brian ConcannonCEOSell4,765$37.20$177,258.00View SEC Filing  
12/1/2014Brian ConcannonCEOSell4,765$36.72$174,970.80View SEC Filing  
11/3/2014Brian ConcannonCEOSell4,765$35.86$170,872.90View SEC Filing  
10/13/2014Peter M AllenInsiderSell36,426$35.22$1,282,923.72View SEC Filing  
8/12/2014Ronald MerrimanDirectorSell13,602$35.76$486,407.52View SEC Filing  
8/1/2014Brian ConcannonCEOSell4,380$35.27$154,482.60View SEC Filing  
7/7/2014Pedro P GranadilloDirectorSell5,837$35.97$209,956.89View SEC Filing  
6/12/2014Ronald G GelbmanDirectorSell9,184$34.00$312,256.00View SEC Filing  
6/6/2014Pedro P GranadilloDirectorSell5,837$34.69$202,485.53View SEC Filing  
5/12/2014Susan Bartlett FooteDirectorSell9,184$33.16$304,541.449,939View SEC Filing  
5/7/2014Pedro GranadilloDirectorSell5,837$31.14$181,764.1814,901View SEC Filing  
5/1/2014Brian ConcannonCEOSell4,600$30.01$138,046.00130,307View SEC Filing  
4/28/2014Peter AllenInsiderSell30,000$30.70$921,000.0028,950View SEC Filing  
4/7/2014Pedro GranadilloDirectorSell5,837$31.98$186,667.2614,901View SEC Filing  
4/1/2014Brian ConcannonCEOSell4,600$32.71$150,466.00130,307View SEC Filing  
3/6/2014Ronald GelbmanDirectorSell12,000$36.17$434,040.0039,173View SEC Filing  
3/3/2014Brian ConcannonCEOSell4,600$36.36$167,256.00130,307View SEC Filing  
2/18/2014Susan HanlonVPSell3,690$39.00$143,910.0016,905View SEC Filing  
2/7/2014Jonathan WhiteInsiderSell1,880$38.66$72,680.8025,166View SEC Filing  
2/3/2014Brian ConcannonCEOSell7,600$37.63$285,988.00130,307View SEC Filing  
1/27/2014Susan HanlonVPSell3,206$38.37$123,014.2216,905View SEC Filing  
1/10/2014Susan HanlonVPSell4,000$41.80$167,200.0016,905View SEC Filing  
1/2/2014Brian ConcannonCEOSell7,600$41.58$316,008.00130,307View SEC Filing  
12/16/2013Susan HanlonVPSell4,000$43.50$174,000.0016,905View SEC Filing  
12/9/2013Susan HanlonVPSell3,138$43.07$135,153.6616,905View SEC Filing  
12/2/2013Brian ConcannonCEOSell7,600$42.31$321,556.00130,307View SEC Filing  
11/12/2013Michael KellyInsiderSell61,400$39.70$2,437,580.0010,987View SEC Filing  
11/1/2013Brian ConcannonCEOSell7,600$39.96$303,696.00View SEC Filing  
10/14/2013Michael KellyInsiderSell1,400$40.41$56,574.0011,337View SEC Filing  
9/13/2013Michael KellyInsiderSell1,400$40.36$56,504.0011,337View SEC Filing  
9/3/2013Brian ConcannonCEOSell13,000$39.87$518,310.00115,798View SEC Filing  
8/1/2013Brian ConcannonCEOSell13,000$42.24$549,120.00View SEC Filing  
7/12/2013Michael P KellyInsiderSell1,400$44.10$61,740.00View SEC Filing  
7/1/2013Brian ConcannonCEOSell13,000$41.87$544,310.00View SEC Filing  
6/18/2013Christopher J LindopCFOSell68,628$42.50$2,916,690.00View SEC Filing  
6/14/2013Michael P KellyInsiderSell1,400$42.17$59,038.00View SEC Filing  
6/3/2013Brian ConcannonCEOSell13,000$41.15$534,950.00View SEC Filing  
5/21/2013Christopher J LindopCFOSell42,882$42.00$1,801,044.00View SEC Filing  
5/14/2013Michael P KellyInsiderSell1,400$39.66$55,524.00View SEC Filing  
5/1/2013Brian ConcannonCEOSell13,000$38.66$502,580.00View SEC Filing  
12/3/2012Brian ConcannonCEOSell13,000$40.75$529,750.00View SEC Filing  
11/12/2012Pedro P GranadilloDirectorSell16,000$80.40$1,286,400.00View SEC Filing  
9/4/2012Brian ConcannonCEOSell6,500$73.68$478,920.00View SEC Filing  
9/4/2012Christopher J LindopCFOSell61,783$74.34$4,592,948.22View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Haemonetics (NYSE HAE) News Headlines

Source:
DateHeadline
Arizona State Retirement System Boosts Position in Haemonetics Co. (HAE)Arizona State Retirement System Boosts Position in Haemonetics Co. (HAE)
www.americanbankingnews.com - February 25 at 4:16 AM
Here's Why You Must Add Haemonetics (HAE) to Your PortfolioHere's Why You Must Add Haemonetics (HAE) to Your Portfolio
finance.yahoo.com - February 23 at 4:54 PM
Zacks.com featured highlights include: Lululemon, Haemonetics, NVR, YY and ConocoPhillipsZacks.com featured highlights include: Lululemon, Haemonetics, NVR, YY and ConocoPhillips
finance.yahoo.com - February 23 at 9:24 AM
Luminex (LMNX) Banks on Solid Product Line, Competition RifeLuminex (LMNX) Banks on Solid Product Line, Competition Rife
finance.yahoo.com - February 21 at 9:35 AM
Haemonetics Co. (HAE) Given Consensus Rating of "Buy" by BrokeragesHaemonetics Co. (HAE) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - February 21 at 1:28 AM
$223.09 Million in Sales Expected for Haemonetics Co. (HAE) This Quarter$223.09 Million in Sales Expected for Haemonetics Co. (HAE) This Quarter
www.americanbankingnews.com - February 20 at 6:44 AM
Morgan Stanley Boosts Haemonetics (HAE) Price Target to $77.00Morgan Stanley Boosts Haemonetics (HAE) Price Target to $77.00
www.americanbankingnews.com - February 19 at 10:12 PM
Haemonetics (HAE) Banks on Plasma Franchise, Competition RifeHaemonetics (HAE) Banks on Plasma Franchise, Competition Rife
www.zacks.com - February 12 at 9:05 AM
Haemonetics (HAE) Rating Increased to Buy at Zacks Investment ResearchHaemonetics (HAE) Rating Increased to Buy at Zacks Investment Research
www.americanbankingnews.com - February 9 at 8:58 PM
Haemonetics Co. (HAE) to Post Q4 2018 Earnings of $0.40 Per Share, Barrington Research ForecastsHaemonetics Co. (HAE) to Post Q4 2018 Earnings of $0.40 Per Share, Barrington Research Forecasts
www.americanbankingnews.com - February 9 at 3:36 PM
FY2018 Earnings Estimate for Haemonetics Co. Issued By Jefferies Group (HAE)FY2018 Earnings Estimate for Haemonetics Co. Issued By Jefferies Group (HAE)
www.americanbankingnews.com - February 9 at 1:24 PM
Haemonetics (HAE) Hits a 52-Week High: Whats Driving It?Haemonetics (HAE) Hits a 52-Week High: What's Driving It?
www.zacks.com - February 9 at 9:11 AM
Haemonetics (HAE) Hits a 52-Week High: What's Driving It?Haemonetics (HAE) Hits a 52-Week High: What's Driving It?
finance.yahoo.com - February 8 at 4:24 PM
Analysts Offer Predictions for Haemonetics Co.s Q1 2019 Earnings (HAE)Analysts Offer Predictions for Haemonetics Co.'s Q1 2019 Earnings (HAE)
www.americanbankingnews.com - February 8 at 3:52 PM
Haemonetics Co. Expected to Post FY2018 Earnings of $1.85 Per Share (HAE)Haemonetics Co. Expected to Post FY2018 Earnings of $1.85 Per Share (HAE)
www.americanbankingnews.com - February 8 at 1:24 PM
FY2018 Earnings Estimate for Haemonetics Co. (HAE) Issued By William BlairFY2018 Earnings Estimate for Haemonetics Co. (HAE) Issued By William Blair
www.americanbankingnews.com - February 8 at 1:24 PM
Haemonetics (HAE) Downgraded by TheStreet to "C+"Haemonetics (HAE) Downgraded by TheStreet to "C+"
www.americanbankingnews.com - February 8 at 10:06 AM
Today’s Research Reports on Stocks to Watch: Roku, Inc. and Haemonetics CorporationToday’s Research Reports on Stocks to Watch: Roku, Inc. and Haemonetics Corporation
finance.yahoo.com - February 8 at 8:56 AM
Haemonetics (HAE) Given Outperform Rating at JMP SecuritiesHaemonetics (HAE) Given Outperform Rating at JMP Securities
www.americanbankingnews.com - February 7 at 1:33 PM
Barrington Research Raises Haemonetics (HAE) Price Target to $71.00Barrington Research Raises Haemonetics (HAE) Price Target to $71.00
www.americanbankingnews.com - February 7 at 10:26 AM
Haemonetics (HAE) to Repurchase $260.00 million in  Outstanding Stock Haemonetics (HAE) to Repurchase $260.00 million in Outstanding Stock
www.americanbankingnews.com - February 6 at 11:14 AM
Haemonetics (HAE) Releases FY18 Earnings GuidanceHaemonetics (HAE) Releases FY18 Earnings Guidance
www.americanbankingnews.com - February 6 at 10:02 AM
Haemonetics (HAE) Posts Quarterly  Earnings Results, Beats Expectations By $0.18 EPSHaemonetics (HAE) Posts Quarterly Earnings Results, Beats Expectations By $0.18 EPS
www.americanbankingnews.com - February 6 at 9:42 AM
Haemonetics reports 3Q lossHaemonetics reports 3Q loss
finance.yahoo.com - February 6 at 9:06 AM
Haemonetics 3rd Quarter Fiscal 2018 Earnings Release Available on Investor Relations WebsiteHaemonetics 3rd Quarter Fiscal 2018 Earnings Release Available on Investor Relations Website
finance.yahoo.com - February 6 at 9:06 AM
Global Disposable Blood Bag Market Expected to Reach $580 Million, by 2023 - Allied Market ResearchGlobal Disposable Blood Bag Market Expected to Reach $580 Million, by 2023 - Allied Market Research
www.bizjournals.com - February 5 at 9:07 AM
$226.86 Million in Sales Expected for Haemonetics Co. (HAE) This Quarter$226.86 Million in Sales Expected for Haemonetics Co. (HAE) This Quarter
www.americanbankingnews.com - February 3 at 6:20 AM
Is Surprise Coming for Haemonetics (HAE) This Earnings Season?Is Surprise Coming for Haemonetics (HAE) This Earnings Season?
www.zacks.com - February 2 at 9:09 AM
 Analysts Anticipate Haemonetics Co. (HAE) Will Announce Earnings of $0.44 Per Share Analysts Anticipate Haemonetics Co. (HAE) Will Announce Earnings of $0.44 Per Share
www.americanbankingnews.com - February 1 at 11:54 AM
Haemonetics (HAE) to Release Quarterly Earnings on TuesdayHaemonetics (HAE) to Release Quarterly Earnings on Tuesday
www.americanbankingnews.com - January 30 at 2:56 AM
Head-To-Head Survey: Steris (STE) and Haemonetics (HAE)Head-To-Head Survey: Steris (STE) and Haemonetics (HAE)
www.americanbankingnews.com - January 27 at 11:26 AM
Haemonetics Co. (HAE) Receives Consensus Rating of "Hold" from AnalystsHaemonetics Co. (HAE) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - January 27 at 1:50 AM
Ellen M. Zane Rejoins Haemonetics Board of DirectorsEllen M. Zane Rejoins Haemonetics Board of Directors
finance.yahoo.com - January 25 at 9:08 AM
Comparing Haemonetics (HAE) & Cryolife (CRY)Comparing Haemonetics (HAE) & Cryolife (CRY)
www.americanbankingnews.com - January 22 at 1:20 AM
Zacks: Brokerages Expect Haemonetics Corporation (HAE) Will Announce Quarterly Sales of $226.86 MillionZacks: Brokerages Expect Haemonetics Corporation (HAE) Will Announce Quarterly Sales of $226.86 Million
www.americanbankingnews.com - January 17 at 2:47 PM
Technical Perspectives on Medical Supplies Stocks -- DENTSPLY SIRONA, Baxter, Haemonetics, and Hill-RomTechnical Perspectives on Medical Supplies Stocks -- DENTSPLY SIRONA, Baxter, Haemonetics, and Hill-Rom
www.prnewswire.com - January 16 at 6:24 AM
$0.44 EPS Expected for Haemonetics Corporation (HAE) This Quarter$0.44 EPS Expected for Haemonetics Corporation (HAE) This Quarter
www.americanbankingnews.com - January 15 at 9:04 AM
Haemonetics (HAE) Cut to Hold at Zacks Investment ResearchHaemonetics (HAE) Cut to Hold at Zacks Investment Research
www.americanbankingnews.com - January 10 at 3:52 PM
Haemonetics Corporation (HAE) to Post Q3 2018 Earnings of $0.45 Per Share, Jefferies Group ForecastsHaemonetics Corporation (HAE) to Post Q3 2018 Earnings of $0.45 Per Share, Jefferies Group Forecasts
www.americanbankingnews.com - January 10 at 12:38 PM
Haemonetics Corporation (HAE) to Post FY2019 Earnings of $2.00 Per Share, Jefferies Group ForecastsHaemonetics Corporation (HAE) to Post FY2019 Earnings of $2.00 Per Share, Jefferies Group Forecasts
www.americanbankingnews.com - January 9 at 11:56 PM
HAE Crosses Above Average Analyst TargetHAE Crosses Above Average Analyst Target
www.nasdaq.com - January 8 at 3:26 PM
Haemonetics (HAE) PT Raised to $75.00 at Jefferies GroupHaemonetics (HAE) PT Raised to $75.00 at Jefferies Group
www.americanbankingnews.com - January 8 at 8:02 AM
Mark W. Kroll Sells 7,118 Shares of Haemonetics Corporation (HAE) StockMark W. Kroll Sells 7,118 Shares of Haemonetics Corporation (HAE) Stock
www.americanbankingnews.com - January 3 at 9:28 PM
Haemonetics Corp. (HAE) Has Broken Out To A New High For The YearHaemonetics Corp. (HAE) Has Broken Out To A New High For The Year
www.nasdaq.com - January 2 at 3:25 PM
Morgan Stanley Turns Bullish On Haemonetics, Raymond James Moves To The SidelinesMorgan Stanley Turns Bullish On Haemonetics, Raymond James Moves To The Sidelines
www.msn.com - January 2 at 3:25 PM
Haemonetics (HAE) Upgraded at Raymond James FinancialHaemonetics (HAE) Upgraded at Raymond James Financial
www.americanbankingnews.com - January 2 at 11:04 AM
Haemonetics Corporation (HAE) Receives Average Recommendation of "Hold" from BrokeragesHaemonetics Corporation (HAE) Receives Average Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - January 2 at 1:32 AM
Haemonetics Corp. :HAE-US: Earnings Analysis: Q2, 2018 By the Numbers : January 1, 2018Haemonetics Corp. :HAE-US: Earnings Analysis: Q2, 2018 By the Numbers : January 1, 2018
finance.yahoo.com - January 1 at 3:22 PM
Zacks: Analysts Expect Haemonetics Corporation (HAE) Will Announce Quarterly Sales of $226.94 MillionZacks: Analysts Expect Haemonetics Corporation (HAE) Will Announce Quarterly Sales of $226.94 Million
www.americanbankingnews.com - December 31 at 5:00 AM
Haemonetics Corporation (HAE) Expected to Post Earnings of $0.44 Per ShareHaemonetics Corporation (HAE) Expected to Post Earnings of $0.44 Per Share
www.americanbankingnews.com - December 29 at 3:22 PM

SEC Filings

Haemonetics (NYSE:HAE) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Haemonetics (NYSE:HAE) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Haemonetics (NYSE HAE) Stock Chart for Sunday, February, 25, 2018

Loading chart…

This page was last updated on 2/25/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.